Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 8Lung Neoplasms 2Neuroendocrine Tumors 1Neuroendocrine Prostate Cancer 1Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Bites and Stings 1

Interventions

pembrolizumab 3enzalutamide 2blinatumomab 2abiraterone 2Stents 2Neoadjuvant Therapy 2Immune Checkpoint Inhibitors 2Cytochrome P-450 Enzyme System 2soybean oil, phospholipid emulsion 1durvalumab 1dostarlimab 1cemiplimab 1camrelizumab 1atezolizumab 1Surgical Procedures, Operative 1Surgical Instruments 1Radiotherapy, Conformal 1Radiotherapy 1Passive Cutaneous Anaphylaxis 1Palliative Care 1Nephrotomy 1Nephrostomy, Percutaneous 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Morphine 1Lidocaine 1Levobupivacaine 1Immunotherapy 1Hydroxyurea 1Etoposide 1Etanercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bites and Stings × AMG 757 × Clear all
NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Amgen

Phase 1 Active not recruiting
184 enrolled
Thoracic

Bites and Stings, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡